STOCK TITAN
  1. Home
  2. Sec-filings
  3. BCDA
  4. [8-K] BioCardia, Inc. Reports Material Event

BioCardia CEO to present at H.C. Wainwright 2026

BioCardia plans a prerecorded presentation and investor meetings at the September 2026 H.C. Wainwright Global Investment Conference to discuss CardiAMP and related platforms.

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

BioCardia, Inc. (BCDA) reported that President and Chief Executive Officer Peter Altman, Ph.D., will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14-16, 2026.

Altman is expected to discuss regulatory progress for the CardiAMP autologous cell therapy in Japan and the United States, the ongoing CardiAMP HF II pivotal trial, and the company’s Helix transendocardial delivery and Heart3D fusion imaging platforms, as well as related business development activities. BioCardia’s prerecorded presentation is expected to be available to conference participants beginning September 11, 2026, and management plans to hold one-on-one investor meetings during the event.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Conference dates September 14-16, 2026 H.C. Wainwright 28th Annual Global Investment Conference
Presentation availability date September 11, 2026 Prerecorded conference presentation expected to be available to participants
Press release date September 10, 2026 Date BioCardia announced its participation and program updates
CardiAMP autologous cell therapy medical
"update on BioCardia’s progress advancing its CardiAMP autologous cell therapy"
CardiAMP HF II pivotal trial medical
"the ongoing CardiAMP HF II pivotal trial, and the Company’s Helix"
Premarket Approval regulatory
"potential for the CardiAMP HF II trial to support Premarket Approval"
Premarket approval is the formal regulatory clearance required before certain medical devices can be sold, based on detailed evidence that the product is safe and effective. For investors, it’s a major milestone because receiving approval typically clears the way for commercial sales and reduces regulatory uncertainty, while failure or delays can block revenue and raise the risk profile; think of it like a safety certificate needed before a new car model can be sold.
transendocardial delivery medical
"the Company’s Helix transendocardial delivery and Heart3D fusion imaging"
fusion imaging medical
"Helix transendocardial delivery and Heart3D fusion imaging platforms"
Fusion imaging combines two or more medical imaging methods — such as ultrasound, CT, MRI or PET — into a single aligned view that overlays detailed anatomy with functional or molecular information. That clearer, more complete picture improves diagnosis, treatment planning and procedural guidance, which can increase demand for specialized scanners, software and services and influence reimbursement and revenue prospects for companies developing these technologies; think of it as layering a roadmap over live traffic camera feeds so decisions are faster and more accurate for doctors.
allogeneic cell therapies medical
"CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s"

FAQ

What event did BioCardia (BCDA) announce in this Form 8-K?
BioCardia announced that President and CEO Peter Altman, Ph.D., will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City, discussing CardiAMP, CardiAMP HF II, Helix, Heart3D, and business development activities.

When and where will BioCardia (BCDA) present at the H.C. Wainwright conference?
BioCardia’s CEO will present at the H.C. Wainwright 28th Annual Global Investment Conference, held at the Lotte New York Palace Hotel in New York City from September 14-16, 2026.

What key programs will BioCardia (BCDA) highlight at the conference?
The company plans to provide updates on CardiAMP autologous cell therapy toward potential regulatory approval in Japan and the U.S., the CardiAMP HF II pivotal trial, and the Helix transendocardial delivery and Heart3D fusion imaging platforms.

Will BioCardia (BCDA) webcast its H.C. Wainwright conference presentation?
The company states the presentation is prerecorded and expected to be available to conference participants beginning September 11, 2026. BioCardia will not host a separate webcast in connection with the conference.

Can investors meet with BioCardia (BCDA) management during the conference?
Yes. The company states that Peter Altman, Ph.D., and members of management will be available for one-on-one meetings with investors, which may be requested through the H.C. Wainwright conference portal or representatives.

What forward-looking areas does BioCardia (BCDA) discuss in the press release?
Forward-looking statements address regulatory submissions in Japan and the U.S., the potential for the CardiAMP HF II trial to support Premarket Approval, potential Helix and Heart3D clearances, business development, and anticipated milestones, all subject to risks noted in BioCardia’s SEC filings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0000925741 0000925741 2026-09-10 2026-09-10
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): September 10, 2026
 
BIOCARDIA, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
 
001-38999
 
23-2753988
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
 
320 Soquel Way
Sunnyvale, California 94085
 
(Address of principal executive offices and zip code)
 
 
Registrant’s telephone number, including area code: (650) 226-0120
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001
BCDA
The Nasdaq Capital Market
 
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter) ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
Item 8.01 Other Events.
 
On September 10, 2026, BioCardia, Inc. issued a press release announcing that Peter Altman, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held at the Lotte New York Palace Hotel in New York City, September 14-16, 2026.
 
A copy of the press release is attached hereto as Exhibit 99.1 to this current report on Form 8-K.
 
The information furnished pursuant to this Item 8.01, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, nor shall it be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly set forth by specific reference in such filing. 
 
Item 9.01   Financial Statements and Exhibits.
 
(d) Exhibits
 
Exhibit No.
 
Description
99.1
104
 
BioCardia, Inc. press release dated September 10, 2026
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
BIOCARDIA, INC.
 
 
 
/s/ Peter Altman, Ph.D.
 
Peter Altman, Ph.D.
 
President and Chief Executive Officer
 
 
 
Date: September 10, 2026
 
 
 

Exhibit 99.1

 

BioCardia to Present CardiAMP Regulatory and Corporate Progress at
H.C. Wainwright 28th Annual Global Investment Conference

 

SUNNYVALE, Calif. – September 10, 2026 – BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that Peter Altman, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held at the Lotte New York Palace Hotel in New York City, September 14-16, 2026.

 

Dr. Altman will provide an update on BioCardia’s progress advancing its CardiAMP® autologous cell therapy toward potential regulatory approval in Japan and the United States, the ongoing CardiAMP HF II pivotal trial, and the Company’s Helix™ transendocardial delivery and Heart3D™ fusion imaging platforms. He will also discuss the Company’s business development activities around its cell therapy and cardiac biotherapeutic delivery technologies.

 

Recent Business Highlights

 

CardiAMP Autologous Cell Therapy for Ischemic Heart Failure (BCDA-01)

 

●

BioCardia is preparing a Shonin pre-market regulatory submission to Japan’s Pharmaceutical and Medical Device Agency (PMDA) for approval of CardiAMP Cell Therapy for ischemic heart failure, targeted for the fourth quarter of 2026. PMDA’s formal Consultation Record of Advice supports a regulatory submission based on the Company’s three completed clinical trials and noted that the positive outcomes observed in the clinical data were credible.

●

In the United States, FDA meeting minutes received in June confirmed that the ongoing randomized, double-blind CardiAMP HF II pivotal trial may support Premarket Approval (PMA) of CardiAMP Cell Therapy for ischemic heart failure of reduced ejection fraction.

●

CardiAMP HF II is actively enrolling in the United States. The confirmatory Phase III study is evaluating CardiAMP Cell Therapy in patients with ischemic heart failure and is designed to provide additional evidence supporting potential U.S. approval.

 

Helix Transendocardial Delivery Platform

 

●

In August, BioCardia announced FDA confirmation of meeting minutes supporting a follow-on De Novo pre-submission for the Helix Transendocardial Delivery Catheter System. BioCardia intends to submit the follow-on pre-submission incorporating FDA advice during the third quarter of 2026.

 

●

An independent FDA clearance of Helix has the potential to expand BioCardia’s opportunities to partner with developers of investigational cell, gene and protein therapeutics requiring targeted delivery to the heart.

 

Heart3D Fusion Imaging

 

●

BioCardia is advancing its proprietary Heart3D Fusion Imaging platform with its partner CART-Tech, designed for procedure planning and real-time navigation during interventional cardiac procedures, toward a potential FDA 510(k) submission.

●

The Company believes the combination of Helix targeted cardiac delivery and Heart3D image-guided navigation represents a differentiated technology platform with potential applications across a broad range of cardiac cell, gene and protein therapies.

 

 

H.C. Wainwright Conference Details

 

Dates: September 14-16, 2026

 

Location: Lotte New York Palace Hotel, New York City

 

Presenter: Peter Altman, Ph.D., President and Chief Executive Officer, BioCardia

 

BioCardia’s conference presentation has been prerecorded and is expected to be available to conference participants beginning Friday, September 11, 2026. BioCardia will not host a separate webcast in connection with the conference.

 

Investors interested in learning more about BioCardia may view the Company’s current corporate presentation on the investor section of the BioCardia website: www.biocardia.com

 

Dr. Altman and members of BioCardia management will also be available for one-on-one meetings with investors during the conference. Conference attendees may request meetings through the H.C. Wainwright conference portal or their H.C. Wainwright representative.

 

About BioCardia

 

BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph® vascular navigation product platforms, and soon the Heart3D fusion imaging platform. BioCardia selectively partners on biotherapeutic delivery with peers developing important biologic therapies. For more information, visit www.biocardia.com.

 

Forward-Looking Statements

 

This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, statements relating to the timing and potential outcome of BioCardia’s regulatory submissions in Japan and the United States; the potential for the CardiAMP HF II trial to support Premarket Approval; submission for and subsequent market clearance of the Helix Transendocardial Delivery Catheter; development and regulatory clearance of Heart3D Fusion Imaging; business development and partnering opportunities; and the achievement of anticipated upcoming milestones.

 

These forward-looking statements are made as of the date of this press release. We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release.

 

 

Factors that could cause or contribute to such differences include, but are not limited to, the Company’s liquidity position and its ability to raise additional funds, as well as the Company’s ability to successfully progress its clinical trials and regulatory programs. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 24, 2026, under the caption titled “Risk Factors” and in its subsequently filed Quarterly Reports on Form 10-Q. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

 

###

Media Contact: 
Miranda Peto, Investor Relations
Email: mpeto@BioCardia.com 
Phone: 650-226-0120

 

Investor Contact: 
David McClung, Chief Financial Officer
Email: investors@BioCardia.com
Phone: 650-226-0120

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

5 documents

Press Releases

Other Documents

Keep reading

More on BCDA

Trending in the feed

Open the live feed